Symposium 20: MAFLD and diabetes: call to action

Authors

  • Adriana Álvarez Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v56i3Sup.604

Keywords:

diabetes mellitus, fatty liver disease

Abstract

MAFLD is actually a main cause of chronic liver disease and is estimated that it would be the principal cause of liver transplantation. Metabolic associated fatty liver disease is diagnosed in patients with hepatic steatosis (diagnose by images, biomarkers, scores or biopsy) when they have the following three metabolic conditions: obesity/overweight, diabetes and metabolic dysregulation, either alone or in combination1.

MAFLD encompasses an spectrum that include the simple esteatosis (SE), steato-hepatitis (SH) and cirrhocis (CI) and have associated complications like hepatocarcinoma (HC).

Author Biography

Adriana Álvarez, Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Staff Physician of the Diabetes Section of the same Service and Coordinator of the Diabetes Education Area

References

I. Eslam M, Newsome PN, Sarin Sk, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202-209.

II. Younossi Z, Anstee QM, Marietti M, Hardy T, et al. Global burden of NAFLD and NASH: trends, predictions, risks factors and prevention. Nat Rev Gatroenterol Hepatol 2018 Jan;15(1):11-20.

III. Fainboim H, Tadey I, Dirchwolf M, et al. Primer estudio en la población de Buenos Aires de prevalencia de virus B, virus C y esteatosis hepática no alcohólica. Acta Gastroenterol Latinoamer 2013;43(Supp.1):S14.

IV. Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, aterosclerosis and NASH: Cause or consequence? J Hepatol 2018; 68:335-352.

Downloads

Published

2022-09-01

How to Cite

Álvarez, A. (2022). Symposium 20: MAFLD and diabetes: call to action. Journal of the Argentine Society of Diabetes, 56(3Sup), 105–105. https://doi.org/10.47196/diab.v56i3Sup.604

Issue

Vol. 56 No. 3Sup (2022): September/December 2022

Section

Symposium Part 4

License

Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.